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Structural variations of the benzylphenoxyacetamide (BpA) molecular skeleton were explored 
as a viable starting point for designing new anti-glioblastoma drug candidates. Hand-to-hand 
computational evaluation, chemical modifications, and cell viability testing were performed to explore 
the importance of some of the structural properties in order to generate, retain, and improve desired 
anti-glioblastoma characteristics. It was demonstrated that several structural features are required to 
retain the anti-glioblastoma activity, including a carbonyl group of the benzophenone moiety, as well as 
4′-chloro and 2,2-dimethy substituents. In addition, the structure of the amide moiety can be modified 
in such a way that desirable anti-glioblastoma and physical properties can be improved. Via these 
structural modifications, more than 50 compounds were prepared and tested for anti-glioblastoma 
activity. Four compounds were identified (HR28, HR32, HR37, and HR46) that in addition to HR40 (PP1) 
from our previous study, have been determined to have desirable physical and biological properties. 
these include high glioblastoma cytotoxicity at low μM concentrations, improved water solubility, and 
the ability to penetrate the blood brain barrier (BBB), which indicate a potential for becoming a new 
class of anti-glioblastoma drugs.
Glioblastoma is the most aggressive and prevalent malignancy of the central nervous system (CNS), with a 
median patient survival rate of about 18 months1–4. Surprisingly, the most effective way to increase survival of 
glioblastoma patients is still extensive surgical resection. However, in many instances, this approach is not feasible 
due to the tumor’s location and its infiltration of highly specialized brain areas5. The current standard of care ther-
apies include maximal surgical resection, followed by radiotherapy plus concomitant and maintenance treatment 
with temozolomide (TMZ), which is one of the few anticancer drugs capable of crossing the blood brain barrier 
(BBB)6. Unfortunately, TMZ-treated tumors develop TMZ-resistance, and recurrent glioblastomas are practically 
incurable7–9. Moreover, numerous clinical trials targeting a variety of glioblastoma-specific pathways, as well as, 
those testing immune checkpoint inhibitors, have been implemented, but have failed to produce a positive out-
come in glioblastoma patients2,10,11.
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Therapeutic strategies that include TMZ in combination with other drugs have been also explored. For instance, 
glioblastomas are characterized by exaggerated lipogenesis, enhanced LDL and cholesterol uptake, and extensive 
phagocytosis and exosome formation12–15. All of these processes require high cholesterol metabolism and uptake for 
a continuous biogenesis of cellular membranes. Therefore, it does not come as a surprise that a combination of cho-
lesterol lowering drugs with TMZ might be a good approach for glioblastoma treatment16. One lipid-lowering drug 
that has attracted attention as a possible candidate for an anticancer regimen is fenofibrate (FF)17–22. FF is a common 
lipid-lowering pro-drug that following its processing by blood and tissue esterases is converted to fenofibric acid 
(FAA), a potent agonist of peroxisome proliferator activated receptor alpha (PPARα) that upregulates fatty acid 
utilization and attenuates glycolysis23–26. Although activation of PPARα may explain some of the observed antican-
cer effects, glioblastoma cells treated with PPARα siRNA retain sensitivity to FF, indicating a PPARα-independent 
mechanism of FF anticancer action. Indeed, our previously published data demonstrate that unprocessed FF (ester) 
accumulates in mitochondrial membrane fraction triggering a severe and immediate inhibition of mitochondrial 
respiration, severe decline in intracellular ATP, and is followed by a massive tumor cell death27. In addition to FF, 
interesting anticancer effects of other lipid lowering drugs, fibrates and statins, have also been reported28–34. A 
ten-year all-cause mortality study involving 7,722 patients treated with different fibrates revealed that the use of 
these metabolic compounds was associated with a significantly lower total mortality and reduced probability of 
death from cancer35. In cell culture and in animal studies, various members of the fibrate family demonstrated a 
broad range of anticancer activities17,20,31,32,34,36–40. These multiple reports encouraged clinical trials in which chronic 
administration of low doses of FF was tested along with chemotherapeutic agents, minimizing their toxicity and 
acute side effects in patients with recurrent brain tumors and leukemia41,42.
Other groups also demonstrated that FF could have PPAR-independent cellular effects including: 
PPAR-independent activation of GDF1523; effects of FF on cell membrane fluidity43; and the FF-induced inhi-
bition of mitochondrial respiration in isolated cardiac and liver mitochondria44,45. Therefore, a growing line of 
evidence supports the interaction of unprocessed FF (ester) with biological membranes, which could be a reason 
for the observed strong anticancer activity of this lipid-lowering drug. However, FF does not cross the BBB, and is 
quickly processed by the blood and tissue esterases to form fenofibric acid (FFA). This acid functions as a potent 
peroxisome proliferator activated receptor α (PPARα) agonist, however, it is no longer effective in triggering 
tumor cell death27,46.
We have made several chemical modifications to the FF structure in order to improve the prospective anti-
cancer drug stability, water solubility, tissue penetration, and ultimately, the anti-glioblastoma efficacy. One of the 
resulting compounds, PP1 (Fig. 1), triggered extensive glioblastoma cell death in vitro at concentrations almost 
5-fold lower than FF47. Similar to FF, PP1 inhibited mitochondrial respiration, and demonstrated improved water 
solubility, BBB penetration, and resistance to blood esterases47. However, PP1 accumulation in the mouse brain 
tumor tissue (following oral administration) varies between 5 and 6 μM and may not be sufficient to exert a highly 
effective anti-glioblastoma activity in vivo47. Therefore, we further explored the anti-tumoral contribution of the 
specific chemical moieties in the FF and PP1 structures, to improve the compound anticancer efficacy and its 
ability for more effective accumulation within the brain tumor tissue. As a result, 50 additional compounds were 
generated and analyzed in this study.
Results and Discusson
Overall chemical design of therapeutic compounds. The basic molecular skeleton of fenofibrate (FF) con-
tains a benzylphenoxyacetate structural arrangement (Fig. 1). Although FF shows promising anti-glioblastoma activity 
at 50 µM, this compound is an isopropyl ester that is promptly hydrolyzed into fenofibric acid (FFA) by blood and tissue 
esterases46. An additional disadvantage of FF is that it has low water solubility, and a relatively high concentration is 
required for its anti-tumoral activity (50 μM)27. Therefore, we have selected the benzylphenoxyacetamide (BPA) molec-
ular skeleton as a basis for designing new more potent anti-glioblastoma compounds due to its structural similarity to 
FF, as well as its increased water solubility and higher resistance to hydrolysis (Figs. 1 and 2A).
Figure 1. Comparison between FF, FFA, and PP1 (modified FF47) structural and functional (anti-cancer) 
properties. The information regarding the compounds water solubility, stability in human blood, penetration of 
the blood brain barrier (BBB), and in vitro cytotoxicity were previously reported27,46,47.
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Four specific regions of the BPA were subsequently designated for chemical modification in order to deter-
mine how the nature of the substitutions may alter its anti-glioblastoma activity (Fig. 2A). Structural variations to 
the chosen regions include exchange of halogens (region A); addition or removal of oxygen, methylene, carbonyl 
groups (region B); addition or removal of hydrogens, one methyl, or two methyl groups (region C); and replace-
ment, removal or addition of one alkyl, two alkyl, one hydroxyalkyl, two hydroxyalkyl, and alkyl with primary, 
secondary, or tertiary group (region D).
All preparations evaluated in this study were initiated with either substituted phenoxyphenols or benzoylphe-
nols (Fig. 2B; Methods A–C). The phenols were first converted into their corresponding sodium salts. Due to the 
differences in acidity of these two groups of compounds (pKa of approximately 10 for phenoxyphenols and 8 for 
benzoylphenols), two different bases were used. The first base, sodium hydroxide in water/benzene was a suffi-
ciently strong base (pKa ~15.7) and was used for preparation of sodium salts of both groups of phenols (Fig. 2B; 
Method A). A Deen-Stark distilling receiver was used to azeotropically remove water. Therefore, a dry white 
powdery sodium phenoxide resulted and was used in a second step which adds bromoalkanoic esters to perform 
nucleophilic substitution. Isolated yields were almost quantitative. However, for the more acidic benzoylphenols, 
one-pot synthesis in alcohol with anhydrous sodium carbonate was also introduced (Fig. 2B; Method B). This 
approach requires longer time but is simpler, safer, more economical and it is the method of choice for the prepa-
ration of benzoylphenoxyethanoic acid.
The next step is the preparation of phenoxyethanoic acids from the esters. This was accomplished in one-pot 
synthesis without isolation of the intermediate ester (Fig. 2B; Method C). In this method, the phenol substrate 
was first converted into its sodium salt with sodium hydroxide via Dean-Stark distillation with molecular sieves48, 
followed by a reaction with the 2-bromaethanoic ester in isopropanol, and finally a hydrolysis step with aqueous 
sodium hydroxide in isopropanol. These products are easily purified by an acid-base extraction. This is the pre-
ferred method for direct preparation of phenoxyethanoic acids, which are the intermediates for preparation of 
targeted amides. Isolated yields are between 85 to 95%.
The starting point for the preparation of each BPA modification in this study is the benzylphenoxyacetic 
acid derivative. For amides, although there is a plethora of synthetic methods for transformation of acids into 
amides, many of these methods cannot be successfully applied to the preparation of all the amides included 
in this study. For instance, employing a well-established amide preparation that utilizes DCC and EDC based 
activation agents49 for direct carboxylic acid conversion to amide could not be used to create the amide of 
2,2-dimethylbenzylphenoxyacetic acid. This is due to a combination of steric hindrance and lower reactivity of 
the activated carboxylic acid. However, when the corresponding carboxylic acid chloride is used, almost quanti-
tative conversion of carboxylic acid into targeted amides is achieved (Fig. 2C).
For formation of reduced forms of the targeted amides, preparation was performed via selective reduction 
(Fig. 2D). For one of the reduction methods, catalytic hydrogenation, such as that performed with 3% palladium 
(Pd) on carbon, removes halogens, reduces the carbonyl group to a methylene group, and reduces the aromatic 
ring that contains chlorine. This reaction is carried out at room temperature and in a hydrogen environment at 
atmospheric pressure. The isolated yield is almost quantitative. One product (HR1) was prepared in this way by 
reducing HR40 (PP1) (Fig. 2D). Selective reduction of the carbonyl group created HR2 from HR40 and was 
accomplished by using a combination of sodium borohydride and trifloroacidic acid at 5 °C (Fig. 2D). In this case, 
the product had to be separated from the starting material by chromatography, so the isolated yield was only 72%.
To further increase the water solubility of basic BPA, ammonium salts were prepared. Hydrochloric salts were 
prepared by simple mixing of the corresponding BPA with concentrated hydrochloric acid followed by water 
evaporation. Then, methylation of the basic BPA was performed with acetone as the solvent, and methyl iodide as 
the methylating reagent. The product, HR36, was crystalized directly from the reaction mixture (Fig. 2E).
Biological, chemical and computational testing of therapeutic compounds. As mentioned above, 
it was demonstrated that FF possesses anti-glioblastoma activity. However, there are several FF properties that 
make it impractical for anticancer treatment27,46. In our previous study, we reported that some amide derivatives 
of FF, including PP1, were more potent in eliminating glioblastoma cells than FF47. These amides belong to the 
large family of BPA50.
One fundamental challenge for the design of CNS penetrant drugs is the need to cross the blood-brain bar-
rier (BBB). But, BBB-permeable compounds form a very small subset of oral drugs currently in existence, and 
experimental models for testing BBB penetration is quite complex. Therefore, an independent indicator of the 
BBB penetration was needed for the initial screening and selection of a large number of compounds (BPA vari-
ants) to evaluate their potential for reaching the intracranial tumor site at therapeutically relevant concentrations. 
Prior to the preparation of all BPA variant compounds in this study, we performed extensive molecular modeling 
to describe their physicochemical properties. A cell viability (CV) assay was then performed using the LN229 
human glioblastoma cell line, and the cells were treated with BPA variants at 25 μM for 72 hours. The results of 
this computational characterization and cell viability testing are outlined in Figs. 3–10.
One currently accepted way to define physicochemical properties is by using a weighted scoring approach, 
known as the Central Nervous System – Multiparameter Optimization (CNS-MPO)51–53. The CNS-MPO algo-
rithm uses a weighted scoring function that assesses 6 key physicochemical properties (clogP, clogD, MW, TPSA, 
HBD, and pKa) that indicate relative BBB penetration. The CNS-MPO scale is between 0 and 6.0, with scores 
≥4.0 widely used as a cut-off to select compounds for hit CNS therapeutic drug discovery programs53. The val-
idation of this approach utilizes a library of 616 compounds to evaluate the experimental distribution of the 
computed parameters incorporated into CNS-MPO scores52,53. It was found that CNS-MPO scores of 1–2 (0%), 
2–3 (11.6%), 3–4 (40.8%), 4–5 (53.8%) and 5–6 (81.1%) correlate with the increased probability (%) of drugs to 
be found in the brain54.
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In addition, parameters that are routinely used for a Quantitative Structure Activity Relationship (QSAR) 
study are molecular polarizability (MP), minimal molecular projection area (MPA), and water solubility (LogS). 
These parameters are not incorporated into the CNS-MPO score, however they are also considered as factors that 
Figure 2. Panel (A) Regions of the BPA skeleton selected for modification (circles). These regions were 
subsequently modified as per legend in search of the optimal anti-glioblastoma drug. Panel (B) Schematic 
illustration of the procedure to develop esters of substituted phenoxyacetic esters and acids. Panel (C) Schematic 
illustration of the procedure for substituted phenoxyacetamides. Panel (D) Schematic illustration of the selective 
reduction of HR40 (PP1) to obtain HR1 and HR2. Panel (E) Schematic illustration of the procedure to develop 
ammonium salts of HR34.
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affect BBB penetration. Therefore, in the associated figures below, these additional parameters were defined and 
calculated for each BPA-derived compound analyzed in this study. Comparing these values is a valuable tool for 
understanding how different substituents may change polarization- and dispersion-type interactions with the 
active sites of their interacting proteins55.
Molecular Polarizability (MP) is a response of electron distribution to an externally-applied static electrical 
field. It was postulated that an MP between 30–40 is optimal for a molecule to bind to a biotarget56. The minimal 
projected area (MPA) is also very important for drug transport and ultimately for drug activity. For instance, in 
recent studies by Cha, Müller, and Pos, a distinct phenotypical pattern of drug recognition and transport for the 
G616N variant was reported, indicating that drug substrates with MPA over 70 Å2 are less well transported than 
the smaller substrates57,58. Finally, water solubility (LogS) of −4.5 and greater are indicators of acceptable water 
solubility59,60 of the studied compounds.
The BBB permeation propensity of all studied compounds is also indicated by the decimal logarithm of brain 
to-plasma concentration ratio (logBB) value, which is derived from the modified Clark’s equation: logBB = 0.152 
ClogP -0.0148PSA + 0.139 30. LogBB was also calculated for the compounds in this study, and is listed in the 
corresponding tables (Figs. 3–10. It has been shown that chemical compounds with logBB > 0.3 readily cross 
the BBB, while those with logBB < −1.0 are poorly distributed to the brain61. Finally, the rate of passive diffusion 
is inversely proportionate to the square root of molecular size (Graham’s law62), which is also included in our 
compound analysis.
Surprisingly, simple amide derivatives of FF, such as AA, MAA, and DMA (Fig. 3), have not been previously 
synthesized. But, in our quest for a better anti-glioblastoma drug, we began with preparation of these three small 
compounds, and an evaluation of their anti-glioblastoma activity as well as their potential ability to cross the BBB. 
Computed physicochemical parameters for FF, FFA, MA, DMA and AA and their anti-glioblastoma activity are 
presented in Fig. 3B. Each of the three amides showed better anti-tumor activity than FF. In fact, the simple amide 
AA is twice as potent, and the dimethyl amide DMA almost four times more potent, as FF at 25 µM (Fig. 3A). 
Computed CNS-MPO scores for the three amides are almost identical, around 3.5, suggesting that the likelihood 
of these compounds penetrating the BBB is around 40%. All estimated MPA for these molecules are between 35 
and 50 Å2 so, based on their size alone they should be capable of crossing the cell membrane57,63. Therefore, MPA 
results presented in Fig. 3 confirm our postulate that the simple amides of FFA are viable structural motifs for 
exploring and possibly improving the anti-glioblastoma activity of FF.
Since our previously reported drug candidate PP1 (HR40) has a very potent activity against glioblastoma 
tumor cells47, we turned our attention to larger molecules based on this BPA structure. To evaluate the products 
of the following structural modifications, we used PP1 as a standard of comparison. We proceeded, by inves-
tigating the importance of the second aromatic ring in BPA, the conjugation of the carbonyl group, and the 
presence of a chlorine atom. All computed parameters for resulting compounds (HR1-HR5) (Fig. 4) suggest that 
these compounds will have moderately desirable physical properties for BBB penetration. ClogPs values are in 
Figure 3. Anti-glioblastoma activity and computed physical properties of fenofibrate (FF) and its simple 
amides. Panel (A) Cell viability (MTT assay) following exposure to the indicated derivatives of FF (25 μM, for 
72 hrs). (Panel B) Computed physical properties of fenofibrate and its simple amides. CV = Cell viability (% 
of control) mean ± SD at 25 μM; ClogP = calculated partitioning; HBD = hydrogen bond donor at pH = 7; 
HBA = hydrogen bond acceptor at pH = 7; logBB = calculated blood-brain partition; MP = Molecular 
polarizability(Å3); PSA = Polar surface area (Å2); MPA = Minimal projection area (Å2); LogS = Aqueous 
solubility (mg/ml); MPO = Central nervous system multiparameter optimization (CNS MPO).
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the middle of the desirable range 2.0 to 5.0, and MPO values are between 3.5 and 4.5, therefore both suggest a 
possibility for these compounds to accumulate in the CNS (Fig. 4B). However, according to the calculated LogBB 
for these compounds, a low brain penetration ability could be also expected. The cell viability data at 25 μM 
for these 5 compounds (HR1-HR5) showed moderate to low anti-glioblastoma activity (Fig. 4A). Replacing the 
4-chlorobenzoyl moiety of PP1 with a cyclohexylmethyl generates the new drug candidate HR1. However, this 
modification results in a decrease of anti-glioblastoma activity (Fig. 4A). This is a somewhat drastic structural 
change, resulting in conformational and noticeable structural electrostatic potential surface changes (Fig. 4C)64. 
Lipophilicity is higher and molecular polar surface area is substantially lower (from 66.84 for PP1 to 49.77 for 
HR1 (Fig. 4B). However, this modification results in a decrease of anti-glioblastoma activity (Fig. 4A,B). If the 
presence of a polar group in the middle of the molecule is important, then replacement of the carbonyl group 
of the benzophenone moiety of PP1 with an ether group (oxygen atom) should produce a new drug candidate, 
HR4, with similar activity to PP1. However, HR4 has only moderate anti-glioblastoma activity (CV = 58.5%), and 
another candidate in this group, HR5, lost its anti-glioblastoma activity (CV = 90.47%) (Fig. 4A). These results 
indicate that the presence of a second aromatic ring, the carbonyl linker, and chlorine are all important for retain-
ing anti-glioblastoma activity of PP1.
Additionally, it is also important to assess the significance of the halogen atoms on the BPA skeleton. It is well 
documented that substituting hydrogen with fluorine substantially changes molecular polarizability (MP) and 
lipophilicity, and increases the binding affinity to targeted proteins65. Also, halogen bonding is stronger between 
chloro-aryls and carbonyl compounds, than between corresponding fluoro-aryls. Therefore, the computed data, 
as well as, the cell viability data of modified variants of PP1 in which the chlorine atom was replaced with fluorine 
(HR8-HR11) are presented in Fig. 5. Although, the ester of fluoro-FF (HR8) has virtually the same activity (CV) 
Figure 4. The BPA derivatives with methylene and oxygen in region B. Panel (A) Cell viability (MTT assay) 
following exposure to the indicated derivatives of FF (25 μM, for 72 hrs). Panel (B) CV = Cell viability (% 
of control) mean ± SD at 25 μM; ClogP = calculated partitioning; HBD = hydrogen bond donor at pH = 7; 
HBA = hydrogen bond acceptor at pH = 7; ClogBB = calculated blood-brain partition; PSA = Polar surface 
area (Å2); MPA = Minimal projection area (Å2); LogS = Aqueous solubility (mg/ml); MPO = Central nervous 
system multiparameter optimization (CNS MPO). Panel (C) Electrostatic potential map for PP1, HR1, and HR4 
generated by semi-empirical method PM3 as implemented in Spartan ’18 version 1.1.0.
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as FF, other esters (HR6, HR7) are virtually inactive at the same concentration (25 μM) (Fig. 5A). So, further 
exploration of the anti-glioblastoma activity for ester derivatives of FF is not necessary.
Fluoro-PP1 (HR9) has a lower potency than PP1, and therefore, halogen bonding appears to be very impor-
tant for anti-glioblastoma activity in BPAs (Fig. 5A). The order of activity for the tested amides presented in Fig. 5 
is PP1 (HR40) > HR11 > HR9. However, the computed physicochemical parameters do not include an indicator 
of the effect of halogen bonding, which therefore, underestimates the contribution of the chlorine bonding in 
PP1. In addition, electrostatic potential maps for PP1 and HR9 (Fig. 5C) are very similar, therefore they are 
expected to have similar anti-glioblastoma activity in terms of molecular potential. However molecular polariz-
ability MP = 39.25 Å3 for PP1 and MP = 37.05 Å3 for HR9 are quite different indicating different binding capa-
bilities and may explain why HR9 is less active (CV = 35.55%) compared to PP1 (CV = 1.04%). Surprisingly, the 
molecular polarizability of HR11 (39.36 Å3) is quite close to that of PP1 (Fig. 5C), indicating that HR11 might 
have a stronger binding capability to the targeted molecule than HR9, which is reflected by a slightly higher bio-
logical activity of HR11 (Fig. 5A,B). These data indicate that calculated physicochemical properties are not always 
in a full agreement with the predicted biological responses, and once the candidate compounds are preselected, 
they require further validation using relevant cell culture animal models.
The BPA structure was further modified in order to explore the importance of two methyl groups in the 
alpha position (Fig. 2A; Region C). For non-methylated (unsubstituted alpha position) phenoxyamides, the 
Figure 5. Fluoro- vs Chloro-benzylphenoxyacetamide. Panel (A) Cell viability (MTT assay) following exposure 
to modified variants of PP1 in which chlorine atom was replaced (25 μM, for 72 hrs). Panel (B) CV = Cell 
viability (% of control) mean ± SD at 25 μM; ClogP = calculated partitioning; HBD = hydrogen bond donor 
at pH = 7; HBA = hydrogen bond acceptor at pH = 7; ClogBB = calculated blood-brain partition; PSA = Polar 
surface area (Å2); MPA = Minimal projection area (Å2); LogS = Aqueous solubility (mg/ml); MPO = Central 
nervous system multiparameter optimization (CNS MPO). Panel (C) Comparison of electrostatic potential map 
of our fluoro compounds with electrostatic potential map of PP1.
8Scientific RepoRtS |         (2019) 9:17021  | https://doi.org/10.1038/s41598-019-53207-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
physicochemical parameters and biological activity results are presented first in Fig. 6. All computed compounds, 
here, have both acceptable computed polar surface area (PSA) and minimal projected area (MPA), which indicate 
that they can penetrate cellular membranes52,53,57. The estimated CNS-MPO for these amides (HR13-HR17) are 
all more desirable than for PP1 (Fig. 6B). Just based on this data, one would expect these compounds to have at 
least comparable biological activity to, if not better than, PP1. However, they are almost all inactive at the tested 
25 μM concentration (Fig. 6A,B). Therefore, it is obvious that the presence of at least one methyl group is crucial 
for retaining activity.
The computed physical properties for the prepared monomethylated amides (shown in Fig. 7) are closer to the 
estimated physical properties of PP1, in respect to potential for BBB penetration, but their cell toxicity at 25 μM is 
very low (Fig. 7A,B). It is now also clear that two methyl groups are essential for retaining anti-glioblastoma activ-
ity. Comparison of the electrostatic potential for di –, mono-, and non-methylated compounds (HR13, HR18, 
HR21) suggests that a large positive area in the molecule is lost by removing the methyl groups (Fig. 7C). But, 
when a larger non-polar amide moiety is introduced, such as in the creation of HR21 (Fig. 7C), a new positive 
electrostatic potential surface is generated that partially offsets the nonexistence of the methyl group. This is also 
indicated by a computed molecular polarizability (MP) that is slightly higher than that of PP1, resulting in mod-
est activity (CV = 40.7%) for both HR21 and HR22 compared to PP1 (CV = 1.04%) (Fig. 7A,B). So, in spite of 
the slight offset of the electrostatic potential maps, it seems apparent that two methyl groups in the alpha position 
of BPA are essential for retaining anti-glioblastoma activity. Therefore, the structural configuration necessary for 
anti-glioblastoma activity is approximately equal to the FF derivative, AA, introduced in Fig. 3.
After establishing the importance of the 2-(4-chlorobenzoyl)phenoxy-2,2-dimethylacetamide (AA) structural 
skeleton for anti-glioblastoma activity, it is now essential to assess the nature of the amide moiety (Fig. 2A; region 
C). Three groups of AA variants were designed, prepared and tested. The first group of compounds contained an 
amide moiety with neutral pH (Fig. 8) in order to establish the size and structural branching on the amide part 
of the molecule. Again, the physicochemical parameters and biological activity data were compared to our good 
drug candidate PP1. The computed MPAs for HR24-HR30 are acceptable (40–60 Å2) and suggest that based on 
this property alone all of these compounds should have good cell permeability. On the other hand, based on the 
estimated PSA and CNS-MPO data, HR28 should be expected to have a lower probability of penetrating into the 
cell, and possibly lower accumulation in the CNS. This is in spite of the fact that HR28 is very potent in eliminat-
ing glioblastoma cells in vitro (CV = 4.31%) (Fig. 8A,B).
Figure 6. Drug candidates with unsubstituted alpha position of BPA. Panel (A) Cell viability (MTT assay) 
following exposure to modified variants of PP1 with unsubstituted alpha position of BPA (25 μM, for 72 
hrs). Panel (B) CV = Cell viability (% of control) mean ± SD at 25 μM; ClogP = calculated partitioning; 
HBD = hydrogen bond donor at pH = 7; HBA = hydrogen bond acceptor at pH = 7; ClogBB = calculated blood-
brain partition; PSA = Polar surface area (Å2); MPA = Minimal projection area (Å2); LogS = Aqueous solubility 
(mg/ml); MPO = Central nervous system multiparameter optimization (CNS MPO).
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Next, amides with a basic amide moiety are presented in Fig. 9. For these compounds, cell permeabil-
ity is strongly associated with the pH of the media. In acidic media, they are protonated and very hydrophilic. 
Additionally, they can be easily alkylated, which in turn can modify their polarity. All cell testing was done at 
physiological pH (pH = 7.4); therefore, the basic drug candidates were not protonated. Amide HR31 has two 
nitrogen atoms separated by four methylene groups. One nitrogen is part of an amide bond and other is part of a 
primary amine. This compound has a CV value similar to that of 25 μM FF27 (Fig. 9A,B). However, when the car-
bon chain is shortened between the two nitrogens by two carbon atoms and the primary amine is transferred to a 
tertiary amine with two ethyl groups, a new drug candidate, HR32, is formed, with the highest anti-glioblastoma 
activity, thus far (CV = 0.17), and is more potent than PP1 (Fig. 9A). Almost all computed parameters suggest 
that HR32 is a good candidate (Fig. 9B); however, it has a CNS-MPO estimated value that is relatively low (2.97), 
suggesting that it may have a low probability of accumulating in the CNS. But, additionally, both the computed 
logBB and logS for this compound suggest that this, in fact, would be a good drug candidate (Fig. 9B).
The other amides in this group (HR33–HR38) with the exception of HR36, have a good anti-glioblastoma 
activity, including the hydrochloric salt HR35, which in addition has a more promising CNS-MPO value (4.41). 
In fact, HR35 is more potent than its free base HR34 (Fig. 9A). One could argue that this is the result of better 
initial solubility of this hydrochloric salt. However, in the cell culture environment, HR35 should be deproto-
nated and become the free base, HR34, that is less potent (Fig. 9A). The reverse is true in the case of HR37 and 
its hydrochloride salt HR38. The free base, HR37, is more potent than its hydrochloric salt (HR38) (Fig. 9A).
For the alkylated drug candidates, such as methylated HR34, the activity is substantially diminished 
because they cannot be deprotonated. If one examines the computed parameters for HR36, it is apparent that 
the compound is very hydrophilic (ClogP = −0.31; logS = 0.88) and has a very low estimated BBB penetration 
Figure 7. Drug candidates with alpha monomethylated BPA. Panel (A) Cell viability (MTT assay) following 
exposure to modified variants of PP1 with alpha monomethylated BPA (25 μM, for 72 hrs). Panel (B) CV = Cell 
viability (% of control) mean ± SD at 25 μM; ClogP = calculated partitioning; HBD = hydrogen bond donor 
at pH = 7; HBA = hydrogen bond acceptor at pH = 7; ClogBB = calculated blood-brain partition; PSA = Polar 
surface area (Å2); MPA = Minimal projection area (Å2); LogS = Aqueous solubility (mg/ml); MPO = Central 
nervous system multiparameter optimization (CNS MPO). Panel (C) Comparison of the electrostatic potential 
maps di-, mono- and non-methylated drug candidate (HR13, HR18 and HR21) with PP1.
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(logBB = −0.6). Surprisingly the CNS-MPO of HR36 is 4.0, which would suggest that this compound should be 
capable of accumulating in CNS, however it is completely inactive at 25 μM (CV = 98%) (Fig. 9A,B). In conclu-
sion, the best candidate from this group of compounds is HR32, which is more potent than PP1. In addition, 
HR35 and HR37 are also good candidates mostly because of their relatively high CNS-MPO and low CV values. 
In contrast, HR36, which is permanently positively charged, completely loses its anti-glioblastoma activity.
Water solubility is a major obstacle in the proper administration of drug candidates66. One approach to 
increasing water solubility is to introduce hydroxy groups in the non-essential structural area of the compound. 
The amide moiety of new compounds, listed in Fig. 10, seems to be an appropriate location to place one to sev-
eral hydroxy groups. This modification of PP1 starts by replacing the N-methyl group with N-H to make HR39. 
Although CNS-MPO values are virtually identical for PP1 and HR39, the latter has less desirable ClogP and 
LogBB values, indicating potentially lower cell penetration. The resulting cell viability agrees with these estimates 
because HR39 is significantly less potent than PP1 (Fig. 10A,B). This finding suggests that tertiary amides are 
required for high anti-glioblastoma activity.
Introducing rigidity to stabilize a desired drug conformation could result in increased drug potency67 in many 
instances. One of the ways to introduce molecular rigidity is by replacing a linear carbon skeleton with a cyclic 
carbon skeleton. This modification to PP1 resulted in the new drug candidate HR41, which is unfortunately less 
potent than PP1 (Fig. 10A).
Four drug candidates containing two hydroxy groups (HR42, HR43, HR44 and HR46) are also presented 
in Fig. 10. Two of them (HR42 and HR43) are structural isomers, but both are secondary amides, as is HR39. 
Interestingly, HR42 and HR43 activities (CV) are almost identical, indicating that the presence of the tertiary 
amide moiety is more important than the presence of the two hydroxy groups. Two tertiary amides with two 
hydroxy groups, HR44 and HR46, are also structural isomers. They are both more potent than the secondary 
amide, HR39, but the tertiary amide HR46, with two CH2CH2OH moieties, is almost as potent as PP1. However, 
introducing three (HR45) or more (HR57) hydroxy groups slightly decreases the potency, possibly because the 
compounds are becoming substantially more hydrophilic, as is demonstrated by lower Clog, MPO, and logBB 
estimated values (Fig. 10B). In conclusion, from this group (HR39-HR47) the best candidate is HR46 due to its 
low CV value and acceptable CNS-MPO values that are very similar to the prototype drug, PP1 (HR40).
In conclusion, we have identified four drug candidates, similar to PP1 (HR40), that have strong in vitro 
anti-glioblastoma activity, but have physical properties that may contribute to improved brain tumor penetration 
Figure 8. Drug candidates with a pH neutral amide moiety. Panel (A) Cell viability (MTT assay) following 
exposure to modified variants of PP1 with pH neutral amide moiety (25 μM, for 72 hrs). Panel (B) CV = Cell 
viability (% of control) mean ± SD at 25 μM; ClogP = calculated partitioning; HBD = hydrogen bond donor 
at pH = 7; HBA = hydrogen bond acceptor at pH = 7; ClogBB = calculated blood-brain partition; PSA = Polar 
surface area (Å2); MPA = Minimal projection area (Å2); LogS = Aqueous solubility (mg/ml); MPO = Central 
nervous system multiparameter optimization (CNS MPO). H28 activities at 10 μM (38.31 ± 3.50), 5 μM 
(65.90 ± 2.82), and 1 μM (92.75 ± 3.59).
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(Fig. 11). The IC50 concentration of these compounds is around 10 μM, which is an acceptable therapeutic con-
centration for most clinically relevant anticancer drugs68. By exploring the computed structural and functional 
properties of benzylphenoxyacetamide (BPA), along with testing of cell viability, it was demonstrated that two 
methyl groups in the 2-position of BPA are important for retaining anti-glioblastoma activity. Substitution of 
the chloro- substituent in the 4-position of the benzophenone moiety, resulted in a significant loss of anticancer 
activity of the modified compound. The molecular rigidity between the two aromatic rings of the benzophenone 
moiety is essential because both methylene and oxygen replacement of the carbonyl group resulted in lost or 
diminished anti-tumoral activity. It was also demonstrated that tertiary amides are more potent than secondary 
amides, which, in turn, are more potent than primary amides. In tertiary amides, it is important to keep one 
substituent small (methyl), while the other group can be a hydroxy or nitrogen substituted alkyl. In addition 
to the evaluated chemical modifications in the BPA structure, there is still a high degree of flexibility for addi-
tional structural variations predominantly to the amide moiety (Fig. 2A; Region D). Exploring these additional 
structural variations, applying experimental and computational predictors of the BBB penetration, and testing 
drug efficacy in highly relevant brain tumor animal models, will produce more effective anti-glioblastoma drug 
candidates in the future.
Methods
All starting materials were reagent grade and purchased from Sigma–Aldrich, ArkPharm, TCI America, and 
AbaChemScene. 1H-NMR spectra were recorded on Varian Mercury 300 and Varian Mercury 400 Plus instru-
ments in CDCl3, DMSO-d6, using the solvent chemical shifts as an internal standard. Electrospray Mass 
Spectroscopy (EMS) was recorded on Waters LCT Premier XE (that’s a Tof MS) with an ESI source, scanning 
100–2000 m/z with direct injections of 5 µl sample, using a 0.2 ml/min flow of acetonitrile. All molecular physical 
properties were calculated using Marvin Sketch software. All computed molecular descriptors were generated by 
Figure 9. Drug candidates with basic amide moiety - protonated and alkylated. Panel (A) Cell viability (MTT 
assay) following exposure to modified variants of PP1 with basic amide moiety (25 μM, for 72 hrs). Panel (B) 
CV = Cell viability (% of control) mean ± SD at 25 μM; ClogP = calculated partitioning; HBD = hydrogen 
bond donor at pH = 7; HBA = hydrogen bond acceptor at pH = 7; logBB = calculated blood-brain partition; 
PSA = Polar surface area (Å2); MPA = Minimal projection area (Å2); LogS = Aqueous solubility (mg/ml); 
MPO = Central nervous system multiparameter optimization (CNS MPO). H32 CV at 10 μM (41.49 ± 7.94), 
CV at 5 μM (77.76 ± 7.24), and CV at 1 μM (96.80 ± 6.51). H35 CV at 10 μM (56.26 ± 0.59), CV at 5 μM 
(79.34 ± 1.70), and CV at 1 μM (93.64 ± 2.08). H37 CV at 10 μM (47.02 ± 1.23), CV at 5 μM (75.02 ± 1.42), 
and CV at 1 μM (109.20 ± 5.73). H38 CV at 10 μM (52.00 ± 1.86), CV at 5 μM (74.89 ± 1.79), and CV 1 μM 
(97.97 ± 11.41).
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ChemAxon MarvinSketch version 19.4. Electrostatic potential maps were calculated with PM3 semi-empirical 
method as implemented in Spartan ’18 v 1.1.0. NMR and MS spectra for all HR compounds generated in this 
study are included in Supplementary Materials.
Cell culture and viability assays. Human glioblastoma LN-229 cells were maintained as semi-confluent 
monolayer culture in DMEM with 1 g/L glucose, sodium pyruvate, and L-glutamine (Corning) supplemented 
with 10% heat inactivated FBS (Gibco) and P/S (50 units/mL of penicillin and 50 µg/mL of streptomycin) at 37 °C 
in a 5% CO2 atmosphere. Prior to treatment, cells were plated in 96-well plates (BD Falcon) at initial density of 
2 × 104 cells/cm2. Stock solutions of the compounds were prepared in DMSO, diluted in cell culture medium and 
added to the cells in triplicate for every experimental condition 24 h after plating (final concentration 25 µM). 
For the vehicle control, DMSO was used at 0.5%. MTT assay69 (measuring cell metabolic activity) was performed 
after a 72 h incubation in the presence of the compounds, as previously described. Following 1 h incubation with 
MTT, formazan crystals were dissolved in 5 mM HCl in isopropanol and absorbance read at 540 nm. Data rep-
resent mean values expressed as a percentage of the vehicle control ± SD. Phase contrast images of treated cells 
were taken 48 hours following the treatment with a BZ-X800 fluorescence microscope (Keyence) equipped with 
a 20x objective.
Method A. Preparation of isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)acetate (3n). A water (10 ml) solution 
of sodium hydroxide (410 mg; 10.25 mmol), (4-chlorophenyl)(4-hydroxyphenyl)methanone (2.3 g; 0.1 mol) and 
benzene (100 ml) was refluxed for 10 minutes and water was azeotropically removed by using a Deen-Stark dis-
tillation apparatus followed by removal of benzene under reduced pressure. The resulting white powdery sodium 
phenoxide was mixed with dry isopropanol (100 ml) and isopropyl bromoacetate (1.9 g; 10.5 mmol). The resulting 
mixture was stirred with sonication for 1 hour and refluxed for 4 hours. Solvent was evaporated to solid residue 
and mixed with dichloromethane (100 ml) and water (100 ml). The water layer was discarded, and organic layer 
was washed with 5% sodium carbonate (3 × 50 ml) and dried over anhydrous sodium carbonate. After solvent 
evaporation, the resulting white residue was dried under vacuum to give a white solid product; isolated yield of 
Figure 10. Drug candidates with one or several hydroxy groups in the amide moiety. Panel (A) Cell viability 
(MTT assay) following exposure to modified variants of PP1 with one or several hydroxy groups in the amide 
moiety (25 μM, for 72 hrs). Panel (B) CV = Cell viability (% of control) mean ± SD at 25 μM; ClogP = calculated 
partitioning; HBD = hydrogen bond donor at pH = 7; HBA = hydrogen bond acceptor at pH = 7; 
logBB = calculated blood-brain partition; PSA = Polar surface area (Å2); MPA = Minimal projection area (Å2); 
LogS = Aqueous solubility (mg/ml); MPO = Central nervous system multiparameter optimization (CNS MPO). 
PP1 CV at 10 μM (43.67 ± 1.88), CV at 5 μM (70.03 ± 2.04), and CV at 1 μM (98.36 ± 1.61). H46 CV at 10 μM 
(51.97 ± 10.27), CV at 5 μM (86.15 ± 8.50), and CV at 1 μM (103.00 ± 2.98).
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93% (3.1 g). 1H-NMR (400, DMSO-d6) δ 7.79 (2H, d, J = 9.2 Hz), 7.71 (2H, d, J = 8.8 Hz), 6.97 (2H, d, J = 8.8 Hz), 
5.16 (1H, septet, J = 7.2 Hz), 4.67 (2H, s), and 1.28 (6H, d, J = 7. 2 Hz) ppm.
Method B. Isopropyl 2-(3-benzoylphenoxy)-2-methylpropanoate (4f). An isopropanol (300 ml) suspension 
of sodium carbonate (21.2 g; 200 mmol), (3-hydroxyphenyl)(phenyl)methanone (4 g; 20 mmol) and isopropyl 
2-bromo-2-isobutirate (4.2 g; 20 mmol) was refluxed with stirring for 3 days. After cooling to room temperature, 
the resulting white solid was separated by filtration washed with isopropanol (3 × 20 ml). Filtrates were evap-
orated and evaporated to an oily residue. This residue was mixed with water/chloroform (100 ml/200 ml). The 
water layer was discarded, and the chloroform layer was washed with 5% sodium hydroxide (3 × 50 ml), water 
(3 × 50 ml), and dried over anhydrous sodium carbonate. After filtration the chloroform was evaporated to oily 
residue, that standing at 5 °C overnight, gave a white solid in 92% (6 g) isolated yield. 1H-NMR(300 MHz, CDCl3) 
δ 7.77 (2H, d, J = 6.9 Hz), 7.68 (1H, t, J = 6.9 Hz), 7.48 (2H, d, J = 7.5 Hz), 7.5–7.3 (3H, m), 7.27 (1H, s), 7.07 (1H, 
d, J = 6.9 Hz), 5.06 (1H, septet, J = 6.3 Hz), 1.60 (6H, s), and 1.18 (6H, d, J = 6.9 Hz). 13C-NMR (200 MHz, CDCl3) 
δ 173.2, 155.4, 128.6, 137.5, 129.9, 129.0, 128.2, 127.5, 123.8, 123.1, 120.3, 79.4, 69.1, 25.3 and 21.5 ppm
Method C. Acid preparation. Preparation of 2-methyl-2-(4-phenoxyphenoxy)propanoic acid (1e). A water 
(10 ml) solution of sodium hydroxide (0.42 mg;10.5 mmol), benzene (100 ml) and 4-phenoxyphenol (1.86 g; 
10 mmol) was stirred at room temperature for one hour. Water was evaporated away by Dean-Stark distillation. 
The remaining benzene was removed under reduced pressure, and the resulting white powdery residue was mixed 
with isopropanol (200 ml) and isopropyl 2-bromo-2-methylpropanoate (2.1 g; 10 ml). The resulting mixture was 
stirred by sonication at 60 °C for two hours followed by refluxing overnight. After cooling to room temperature, 
5% sodium hydroxide (100 ml) was added and the resulting mixture was refluxed for 2 hours. The solvent was 
evaporated to solid residue mixed with water (150 ml) and acidified with concentrated hydrochloric acid to pH 
~3. The resulting white suspension was mixed with chloroform (100 ml) and the chloroform layer was separated, 
washed with water (3 × 50 ml), and then washed with 10% sodium carbonate (100 ml). The sodium carbonate 
layer was acidified with concentrated hydrochloric acid to pH ~ 3. The white precipitate was separated by filtra-
tion, washed with water and dried at room temperature under a vacuum to give a pure product [92% yield (2.5 g)]. 
1H-NMR (400 MHz, CDCl3) δ 7.31 (2H, t, J = 7.6 Hz), 7.08 (1H, t, J = 7.6 Hz), 6.96 (2H, d, J = 7.6 Hz), 6.93 (4H, 
s), and 1.58 (6H, s) ppm.
Method D. (nitrogen unsubstituted amides). Preparation of 2-(4-(4-chlorobenzoyl)phenox-
y)-2-methylpropanamide (AA). A dichloromethane (10 ml) suspension of fenofibric acid (FFA, 318 mg; 1 mmol) 
and two drops of DMF was stirred at room temperature for 3 hours. The resulting clear dichloromethane solution 
was evaporated at 30 °C under reduced pressure. The remaining white solid residue was dissolved in tetrahydro-
furan (20 ml) and mixed with aqueous ammonia (10 ml; 3.08 g; 0.17 mol) and stirred at room temperature for one 
hour. The resulting mixture was mixed with dichloromethane (50 ml) and water (50 ml). Organic solvent was sep-
arated, washed with water (3 × 50 ml), 5% sodium carbonate (50 ml), and dried over anhydrous sodium carbonate. 
Figure 11. Low magnification phase contrast images of LN229 human glioblastoma cells treated with five 
selected drug candidates at 25 μM concentration (HR28, HR32, HR37,HR46 and PP1 (HR40)). Control cells 
were treated with the equal volume of vehicle (DMSO). Images were taken 48 hours following the treatment. CV 
values for each compound are in parentheses.
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The solvent was evaporated to give white solid product that was recrystallized from dichloromethane-cyclohexane 
to give pure product [93% yield (295 mg)]. 1H-NMR (400, DMSO-d6) δ 7.69 (4H, d + d, J1 = J2 = 8.4 Hz), 7.58 (2H, 
d, J = 8.4 Hz), 7.57 (1H, s), 7.32 (1H, s), 6.97 (2H, d, J = 8.4 Hz), and 1.50 (6H, s) ppm. 13C-NMR (400, DMSO-d6) 
δ 193.7, 175.4, 159.8,137.5, 136.7, 132.1, 131.6, 130.0, 129.0, 118.5, 80.9, and 25.4 ppm.
Method E. (N-methyl amides). Preparation of 2-(4-(4-chlorobenzoyl)phenoxy)-N,2-dimethylpropanamide 
(MA). An aqueous solution (20 ml) of methylamine hydrochloride (675 mg; 10 mmol) and sodium carbonate 
(530 mg; 5 mmol) were mixed with tetrahydrofuran (20 ml) solution of acid chloride prepared, as explained above 
for fenofibric acid (FFA, 318 mg; 1 mmol), and stirred at room temperature for two hours. Dichloromethane was 
added (50 ml) and the organic layer washed with water (3 × 50 ml), 5% sodium carbonate (50 ml) and dried over 
anhydrous sodium carbonate. After evaporation, the resulting oily residue was mixed with cyclohexane (5 ml) 
and left at room temperature overnight. The white needle-like precipitates were separated by filtration and dried 
at 60 °C under vacuum to give pure product [90% yield (300 mg)]. 1H-NMR (400, DMSO-d6) δ 8.09 (1H, q, 
J = 4.8 Hz), 7.67 (2H, d, J = 8.8 Hz), 7.66 (2H, d, J = 8.8 Hz), 7.56 (2H, d, J = 8.8 Hz), 6.93 (2H, d, J = 8.8 Hz), 2.58 
(3H, d, J = 4.8 Hz), and 1.47 (6H, s) ppm. 13C-NMR (400, DMSO-d6) δ 194.0, 174.0, 159.6, 137.6, 136.5, 132.2, 
131.6, 130.2, 129.1, 118.9, 81.2, 30.7, and 25.4 ppm.
Method F. (N ,N-dimethyl amides).  Preparation 2-(4-(4-chlorobenzoyl)phenoxy)-N,N,2- 
trimethylpropanamide (DMA). A mixture of 40% dimethylamine in water (10 ml; 88 mmol) and the acid chloride 
of fenofibric acid (FFA, 1 mmol) was stirred at room temperature for two hours. The reaction mixture was worked 
up as described above (Method E). Product was purified by crystallization from cyclohexane. The isolated yield 
was 89% (310 mg). 1H-NMR (400, DMSO-d6) δ 7.71 (2H, d, J = 8.8 Hz), 7.69 (2H, d, J = 8.8 Hz), 6.89 (2H, d, 
J = 8.8 Hz), 3.02 (3H, s), 2.82 (3H, s), and 1.59 ppm. 13C-NMR (400, DMSO-d6) δ 193.9, 171.5, 159.6, 137.5, 136.7, 
132.6, 131.6, 130.1, 129.1, 116.8, 81.6, 37.3, and 25.9 ppm.
Method G. (pH neutral nitrogen substituted phenoxyacetamides). Preparation of 2-(4-(4-chlorophenoxy)
phenoxy)-N,N-bis(2-hydroxyethyl)-2-methylpropanamide (HR5). A dry dichloromethane (20 ml) solution of 
acid 1k (306 mg; 1 mmol), oxalyl chloride (0.260 ml; 380 mg; 3 mmol) and two drops of DMF was stirred at room 
temperature for 4 hours. The solvent was evaporated, and residue was dissolved in dichloromethane and mixed 
with mixture of tetrahydrofuran (10 ml) in diethanolamine (160 mg; 1.5 mmol) and water (10 ml) with sodium 
carbonate (212 mg; 2 mmol). The resulting mixture was stirred at room temperature for 2 hours and the solvent 
was evaporated under reduced pressure. The solid residue was mixed with dichloromethane (100 ml) and water 
(100 ml). The water layer was discarded, and the organic layer was washed with 5% hydrochloric acid (3 × 50 ml), 
5% sodium carbonate (3 × 50 ml), water (3 × 50 ml) and dried over anhydrous sodium carbonate. The solvent was 
evaporated under reduced pressure to give pure product yielding 84% (330 mg). 1H-NMR (300 MHz, CDCl3) δ 
6.92 (6H, m), 6.82 (2H, d, J = 9.3 Hz), 3.92 (4H, m), 3.66 (2H, t, J = 5.8 Hz), 3.60 (2H, t, J = 5.8 Hz), and 1.65 (6H) 
ppm.
Method H. (basic nitrogen substituted aryloxyacetamides). Preparation of 2-(4-(4-chlorobenzoyl)phenox-
y)-N-(2-(diethylamino)ethyl)-2-methylpropanamide (HR32). A tetrahydrofuran (20 ml) mixture of FFA (318.75; 
1 mmol), oxalyl chloride (0.26 ml; 3 mmol), and two drops of DMF was stirred at room temperature for 2 hours. 
The solvent was evaporated, and solid residue was mixed with dry tetrahydrofuran (20 ml) and cooled down to 
5 °C. This solution was mixed at 5 °C with ice cold water solution (20 ml) of sodium carbonate (212 mg; 2 mol) 
and N,N-diethylethylenediamine (127 mg; 1.1 mmol). Resulting mixture was stirred at room temperature for two 
hours and evaporated to an oily residue. This residue was mixed with dichloromethane (100 ml) and 5% sodium 
carbonate (50 ml). Water layer was discarded, and organic layer was extensively washed with water (10 × 50 ml) 
and dried over anhydrous sodium carbonate. After solvent evaporation, the product was further purified by silica 
gel filtration with 5% triethylamine in ethyl acetate as the solvent. The isolated yield was 75% (317 mg). 1H-NMR 
(400 MHz, CDCl3) δ 7.73 (2H, d, J = 8.8 Hz), 7.69 (2H, d, J = 8.4 Hz), 7.45 (2H, d, J = 8.4 Hz), 7.730 (1H, broad s), 
6.95 (2H, d, J = 8.8 Hz), 3.31 (2H, q, J = 6.0 Hz), 2.49 (2H, t, J = 6.0 Hz), 2.41 (4H, q, J = 7.2 Hz), 1.61 (6H, s), and 
0.87 (6H, t, J = 7.2 Hz) ppm. 13C-NMR (300, CDCl3) δ 194.1, 173.8, 158.9, 138.5, 136.2, 131.8, 131.1, 128.5, 119.4, 
119.0, 81.7, 51.3, 46.6, 36.8, 25.1, and 11.6 ppm.
Method I. (catalytic hydrogenation of benzoylphenoxyacetamides) Preparation of 2-(4-(cyclohexylmethyl)
phenoxy)-N-(2-hydroxyethyl)-N,2-dimethylpropanamide (HR1). An ethanol (50 ml) suspension of amide HR40 
(190 mg; 0.5 mmol) and 3% Pd/C (150 mg) was stirred at room temperature overnight under atmospheric hydro-
gen pressure. The catalyst was removed by filtration and the solvent was evaporated under reduced pressure 
to give a pure product with isolated yield of 96% (320 mg) isolated yield. 1H-NMR (400, CDCl3) δ 6.99 (2H, d, 
J = 8.4 Hz), 6.74 (2H, d, J = 8.4 Hz, 3.79 (2H, t, J = 5.2 Hz), 3.54 (2H, t, J = 5.2 Hz), 3.24 (3H, s), 3.21 (1H, m), 2.39 
(2H, d, J = 7.6 Hz), 1,64 (4H, m), 1.62 (6H, s), 1.45 (2H, m), 1.17 (2H, m), and 0.98 (2H, m) ppm.
Method J. (sodium borohydride – trifluoracetic acid reduction of benzolphenoxyacetamide carbonyl group). 
Preparation of 2-(4-(4-chlorobenzyl)phenoxy)-N-(2-hydroxyethyl)-N,2-dimethylpropanamide (HR2). A dichlo-
romethane (30 ml) suspension of HR40 (190 mg; 0.5 mmol) and fine grinded sodium borohydride (110 mg; 
3 mmol) was kept at −5 °C for one hour. While stirring this suspension at −5 °C, trifluoracetic acid was added 
dropwise (15 ml), over a period of half an hour. The resulting suspension was then stirred at 0 °C for one hour and 
at room temperature for an additional two hours. The suspension was filtered, solid was discarded and dichlo-
romethane filtrate was washed with 5% sodium carbonate (3 × 30 ml), dried over anhydrous sodium carbonate 
and evaporated to oily residue to give crude product. The product was purified by silica gel column chromatog-
raphy with ethyl acetate – dichloromethane (7:3). The isolated yield was 72%. 1H-NMR (400, CDCl3) δ 7.23 (2H, 
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d, J = 8.4 Hz), 7.08 (2H, d, J = 8.4 Hz), 7.01 (2H, d, J = 8.4 Hz), 6.76 (2H, d, J = 8.4 Hz), 3.85 (2H, s), 3.78 (2H, q, 
J = 4.8 Hz), 3.53 (2H, t, J = 4.8 Hz), 3.21 (3H, s), 2.73 (1H, t, J = 5.2 Hz), and 1.62 (6H, s) pppm.
Method K. (hydrochloric salts of basic phenoxyacetamide). Preparation of 4‐{2‐[4‐(4‐chlorobenzoyl)phe-
noxy]‐2‐methylpropanoyl}6-8,17-22,27,46,50,52,53,55,63,67‐1‐methylpiperazin‐1‐ium chloride (HR35). A mix-
ture of concentrated hydrochloric (3 ml) and HR34 (200 mg; 0.5 mmol) was sonicated at room temperature for 
five minutes. The clear water solution was left under stream of nitrogen in hood for several hours to result in a 
white powder product. The white powder was dissolved in dichloromethane (10 ml) and dried over 4 Å molecular 
sieve overnight. The solvent was evaporated, and white residue was dried in vacuum to give 208 mg (95% yield). 
1H-NMR (CDCl3) δ 13.20 (1H, broad s), 7.75 (2H, d. J = 8.8 Hz), 7.71 (2H, d, J = 8.0 Hz), 7.56 (2H, d, J = 8.0 Hz), 
6.90 (2H, d, J = 8.8 Hz), 4.78 (2H, d, J = 13.2 Hz), 3.93 (1H, t, J = 12.8 Hz), 3.52 (1H, t, J = 13.2 Hz), 3.45 (1H, d, 
J = 12.4 Hz), 3.27 (1H, d, J = 10.0 Hz), 2.63 (3H, d, J = 4 Hz), 2.53 (1H, q, J = 10.0 Hz), 1.98 (1H, q, J = 9.6 Hz) and 
1.71 (6H, s) ppm.
Method L. (ammonium salts of basic phenoxyacetamides. Preparation of 4-{2-[4-(4-chlorobenzoyl)phenox-
y]-2-methylpropanoyl}15-1,1-dimethylpiperazin-1-ium iodide (HR36). An acetone (20 ml) solution of HR34 
(100 mg; 0.25 mmol) and methyl Iodide (141 mg; 0.06 ml; 1 mmol) was left in the dark at room temperature for 
three days (~70 hours). During this procedure, a white solid precipitate was formed. This solid product was sepa-
rated by filtration, washed with acetone (3 × 3 ml) and dried at 110 °C for two hours to give pure product in 96% 
yield (130 mg). 1H-NMR (DMSO-d6) δ 7.73 (2H, d, J = 8.8 Hz), 7.71 (2H, d, J = 8.8 Hz), 7.60 (2H, d, J = 7.6 Hz), 
6.93 (2H, d, J = 8.4). 4.06 (2H, broad singlet), 3.86 (2H, broad singlet), 3.30 (2H, broad singlet), 3.25 (2H, broad 
singlet), 3.12 (6H, s) and 1.60 (3H, s) ppm. 13C-NMR (DMSO-d6) δ 193.7, 170.7, 159.1, 137.6, 136.5, 132.7,131.7, 
130.6, 129.1, 117.7, 81.8, 60.7, 51.2, and 26.2 ppm.
Data availability
All data generated or analyzed during this study are included in this published article and the Supplementary 
Information Files. All HR compounds described in the paper are protected under the LSU provisional patent 
29327-056-US2 and can be provided for testing upon request.
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